MTOR and pelvic inflammatory disease: For example, in patients with PIDs where there are gain-of-function mutations affecting PI3K activity, such as APDS 1/2, there is emerging data from in vitro studies to suggest that hyperactivity of mTOR might be amenable to inhibition by mTOR inhibitors such as rapamycin and that this agent might impact on T cell defects in a manner that could theoretically, in turn, affect the clinical course of this PID [27].